Caledon Bioscience Inc.
October 17, 2023
Company Description: Caledon Bioscience is a newly formed, privately held, spin-out. We are a development stage biopharmaceutical company focused on discovering and developing novel and distinctive small molecule therapeutics that modulate G protein-coupled receptors, or GPCR, pathways. Caledon Bioscience is designing proprietary novel small molecule therapeutic candidates with the intent of developing best/first in class therapeutics for the treatment of metabolic, inflammatory and fibrotic diseases with significant unmet medical needs, using our integrated drug discovery platform, medicinal chemistry expertise and deep understanding of the GPCR biology. Caledon Bioscience has active business operations in Canada and the United Kingdom.
http://Currently under construction - www.caledonbio.com
CEO/Top Company Official
Mr. Bruce Pritchard, BA, CA, FioD
Lead Product in Development
Our lead product in development is our GPR84 Antagonist program. Our CTA has been submitted and our Phase 1 clinical trial is expected to commence before the end of 2023.
Development Phase of Primary Product
Number Of Unlicensed Products